SCHEMBL4604745

SCHEMBL4604745

CN(CCCCN)Cc1ccccc1

nearest known ligand 0.75

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.75
PRMT6 Q96LA8 1/20 0.75
PRMT8 Q9NR22 1/20 0.75
SIGMAR1 Q99720 2/20 0.68
MAOB P27338 4/20 0.55
MAOA P21397 1/20 0.55
ACHE P22303 5/20 0.53
LMNA P02545 1/20 0.51
CHRM2 P08172 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25688953 0.98 CARM1 (0.72) CARM1PRMT6PRMT8SIGMAR1MAOB
Hydrochloric Acid SCHEMBL9373710 0.98 CARM1 (0.72) CARM1PRMT6PRMT8SIGMAR1MAOB
SCHEMBL8342032 0.98 CARM1 (0.72) CARM1PRMT6PRMT8SIGMAR1MAOB
SCHEMBL2108172 0.94 CARM1 (0.78) CARM1PRMT6PRMT8SIGMAR1MAOB
Hydrochloric Acid SCHEMBL18730544 0.92 CARM1 (0.75) CARM1PRMT6PRMT8SIGMAR1MAOB
SCHEMBL7225346 0.88 SIGMAR1 (0.85) CARM1PRMT6PRMT8SIGMAR1MAOB
SCHEMBL29733117 0.88 SIGMAR1 (0.85) CARM1PRMT6PRMT8SIGMAR1MAOB
Aminocaproic Acid SCHEMBL8904221 0.86 KDM4A (0.67) CARM1PRMT6PRMT8SIGMAR1MAOB
SCHEMBL1395704 0.86 CARM1 (1.00) CARM1PRMT6PRMT8SIGMAR1MAOB
SCHEMBL1088446 0.86 SIGMAR1 (0.74) CARM1PRMT6PRMT8SIGMAR1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10639300-B2 Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists SOLIS HERRERA ARTURO (MX) 2020-05-05 US disclosed
US-20190111038-A1 COMPOSITIONS AND METHODS FOR TREATING NASAL AND PARANASAL MUCOSA DISEASES WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS SOLIS HERRERA ARTURO (MX) 2019-04-18 US disclosed
EP-3442583-A2 COMPOSITIONS AND METHODS FOR TREATING PARANASAL MUCOSA DISEASES WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS Solis Herrera, Arturo (MX) 2019-02-20 EP disclosed
CN-109069649-A Compositions and methods for treating nasal and paranasal mucosal disorders with nicotinic acetylcholine receptor agonists A·索利斯·赫雷拉 2018-12-21 CN disclosed
WO-2017178897-A2 COMPOSITIONS AND METHODS FOR TREATING PARANASAL MUCOSA DISEASES WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS SOLIS HERRERA ARTURO (MX) 2017-10-19 WO disclosed
US-20170152213-A1 AMINE-CONTAINING LIPIDOIDS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2017-06-01 US disclosed
US-20080306067-A1 Modulators of Chemokine Receptor Activity WEIGAND KLAUS 2008-12-11 US disclosed
EP-1943235-A1 ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Novartis AG (CH) 2008-07-16 EP disclosed
WO-2007048771-A1 ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY NOVARTIS AG (CH) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306067-A1 Modulators of Chemokine Receptor Activity CCR3, CCR1, CCR4 CARM1 2415/4885PRMT6 2608/4885PRMT8 2472/4885
US-20170152213-A1 AMINE-CONTAINING LIPIDOIDS AND USES THEREOF ABCB4, PHOSPHO1, SGMS2 CARM1 699/4885PRMT6 665/4885PRMT8 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.